PRIMO 2023 | Recognizing the need to improve ovarian cancer cure rates

Alexander Olawaiye, MD, FRCOG, FACOG, FACS, University of Pittsburgh, Pittsburgh, PA, describes unmet needs in ovarian cancer, including the inability to diagnose ovarian cancer at early stages. Most patients are diagnosed at stage III/IV, and earlier diagnosis will enhance survival rates. Despite the introduction of PARP inhibitors, only one in five patients are cured, and novel treatment strategies are consequently needed. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.